Crossmark

ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab

Crossref DOI link: https://doi.org/10.1038/s41598-020-59630-y

Published Online: 2020-02-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Agnolon, Valentina https://orcid.org/0000-0002-4950-239X
Contato, Anna https://orcid.org/0000-0001-6637-4361
Meneghello, Anna https://orcid.org/0000-0003-0455-7984
Tagliabue, Elda https://orcid.org/0000-0001-9877-2903
Toffoli, Giuseppe https://orcid.org/0000-0002-5323-4762
Gion, Massimo https://orcid.org/0000-0001-9143-0353
Polo, Federico https://orcid.org/0000-0003-4638-396X
Fabricio, Aline S. C. https://orcid.org/0000-0003-0153-8809
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (12214)

Associazione Italiana per la Ricerca sul Cancro (12214)

Associazione Italiana per la Ricerca sul Cancro (12214)

Associazione Italiana per la Ricerca sul Cancro (12214)

Associazione Italiana per la Ricerca sul Cancro (12214)

Associazione Italiana per la Ricerca sul Cancro (12214)

Regione Autonoma Friuli Venezia Giulia (NADIATools)
License Information

Text and Data Mining valid from 2020-02-20

Version of Record valid from 2020-02-20
More Information

Article History

Received: 3 January 2019

Accepted: 2 January 2020

First Online: 20 February 2020

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below